The effect of terodiline on patients with detrusor instability.
In a double-blind cross-over study the effects and safety of terodiline were evaluated in 24 patients with detrusor instability. The optimum dosage was assessed by comparing 37.5 mg and 50 mg with placebo in three 4-week periods. All patients were assessed subjectively and by cystometry. Two-thirds of patients who completed the trial obtained symptomatic relief with terodiline although objectively there was only a weak dose-related tendency to favour terodiline. Ten patients reported side effects. Two patients did not complete the study due to drug intolerance.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002082:Butylamines / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D001745:Urinary Bladder Diseases / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy*; D014554:Urination / Q000187:drug effects
D002082:Butylamines; D002121:Calcium Channel Blockers; C010637:terodiline